What does 10 CFR 35.315 require for a hospitalized therapy patient?

Section 35.315 requires that the patient be quartered in a private room with a private sanitary facility (or shared only with another therapy patient who also cannot be released), that the room be posted with a Radioactive Materials sign, that visitor duration and location be noted on the door or chart, that items removed from the room be monitored or handled as radioactive waste, and that the Radiation Safety Officer and an authorized user be notified promptly of a medical emergency or death.

What is the release criterion for I-131 patients?

The default screening values in NRC guidance allow release when retained activity is at or below 1,221 MBq (33 mCi) of I-131, or when the measured dose rate at 1 meter is at or below 0.07 mSv/h (7 mR/h). A patient-specific calculation using effective half-life and occupancy factors may permit release at higher activities while still keeping the dose to any other individual below 5 mSv, and written instructions are required whenever the dose to another individual could exceed 1 mSv.

How much dose do family members and caregivers actually receive?

Measured studies consistently find doses well below the 5 mSv constraint when instructions are followed. Reported caregiver effective doses for hospitalized high-activity thyroid cancer patients are typically a few tenths of a millisievert, and family-member doses for released hyperthyroidism patients are similarly low, provided behavioral restrictions on close contact and sleeping arrangements are respected.

What contamination controls are needed for an I-131 therapy room?

Because I-131 is excreted in urine, saliva, sweat, and feces, the room should have absorbent coverings on high-touch and floor surfaces, dedicated linens and utensils, plastic-bagged waste held for decay-in-storage, and a private toilet flushed well. Staff wear gloves and, where appropriate, shoe covers and gowns; the room and staff are surveyed on discharge, and items are monitored before removal per 10 CFR 35.315.

Who oversees inpatient radioiodine therapy radiation safety?

The authorized user directs the medical care and the Radiation Safety Officer, supported by a qualified or board-certified medical physicist, establishes room preparation, dosimetry, contamination control, and release procedures. The program operates under the facility's NRC or Agreement State license and its written radiation protection program.

Radiation Safety for Inpatient I-131 Therapy

Q: When must an I-131 therapy patient be hospitalized?

A patient must be hospitalized when they cannot be released under 10 CFR 35.75 — that is, when the total effective dose equivalent to any other individual from exposure to the released patient could exceed 5 mSv (0.5 rem). This is evaluated using retained activity, measured dose rate, or a patient-specific calculation, and higher administered activities for thyroid cancer more often require inpatient stay than lower activities for hyperthyroidism.

When a radioiodine therapy patient cannot be released under the 5 mSv dose limit, they must be hospitalized — and that single decision triggers a specific, enforceable set of radiation safety duties. Under 10 CFR 35.315, a hospitalized I-131 therapy patient requires a private room and private bath, a Radioactive Materials posting, documented visitor limits, contamination control, staff dosimetry, and monitoring of every item that leaves the room.¹ Getting these right protects nursing staff, visitors, and the public while keeping the program defensible at inspection.

This guide covers the physics of I-131 that drives the hazard, the release calculation that decides admission versus discharge, a worked dose-rate example, room preparation and contamination control, staff and visitor dose management, and the ALARA and regulatory framework that ties it together.¹²³⁴

Introduction

Iodine-131 is the workhorse of unsealed radionuclide therapy, and it is also the radionuclide that most often requires patient confinement. It is used to ablate thyroid remnants and treat differentiated thyroid cancer at high administered activities, and to treat hyperthyroidism at lower activities. The same properties that make it therapeutically effective — a penetrating gamma ray, a beta particle, and biological excretion over days — make it a radiation-protection problem for everyone around the patient.⁵⁶

Most hyperthyroidism patients and many lower-activity cancer patients can be treated as outpatients and released immediately. But when the projected dose to another person would exceed the regulatory limit, the patient is admitted, and the hospital assumes responsibility for a controlled radiation area that happens to be a patient room. The rules for that situation are specific and are enforced under the medical-use regulations and the facility's license.¹²

This is fundamentally a health-physics task layered onto clinical care: the authorized user manages the therapy, while the Radiation Safety Officer and medical physicist manage room preparation, dosimetry, contamination control, and the eventual release decision. Done well, it keeps caregiver and public doses far below limits without compromising nursing care.³⁴⁷

Topic Explanation

The physics of the I-131 hazard

Iodine-131 decays with a physical half-life of about 8.02 days. Each decay emits a beta particle (maximum energy about 606 keV) that delivers the therapeutic dose to thyroid tissue over a short range, and a principal gamma ray at 364 keV that is penetrating enough to create an external radiation field around the patient and to require room shielding considerations.⁵⁸

The external hazard is characterized by the specific gamma-ray constant for I-131, approximately:

Γ \approx 2.2 R \cdot cm^{2} \cdot mCi^{- 1} \cdot h^{- 1}

The internal and contamination hazard arises because iodine is not confined to the thyroid: it is excreted in urine, saliva, sweat, and feces during the days after administration. That biological excretion is why contamination control, not just shielding, dominates the room design, and why measured effective half-lives in patients are shorter than the physical half-life, especially in ablation patients with little remaining thyroid tissue.⁵⁶

Why the release limit drives everything

The regulatory pivot is 10 CFR 35.75: a licensee may release a patient if the total effective dose equivalent to any other individual from exposure to the released patient is not likely to exceed 5 mSv (0.5 rem). If that cannot be assured, the patient is confined, and 10 CFR 35.315 governs the stay.¹ The same regulation requires the licensee to provide written instructions on maintaining doses to others as low as reasonably achievable whenever the dose to any other individual could exceed 1 mSv (0.1 rem).¹²

Key terms:

Retained activity — the activity remaining in the patient at the time of the release decision, which decreases by both physical decay and biological excretion.
Effective half-life ( $T_{eff}$ ) — the combined physical and biological clearance rate, $1/ T_{eff} = 1/ T_{phys} + 1/ T_{bio}$ .
Occupancy factor ( $E$ ) — a factor accounting for the fraction of time and the distance at which another person is exposed to the patient.²

Key Technical Principles

The release calculation

NRC guidance provides three ways to demonstrate compliance with the 5 mSv limit, in increasing order of sophistication:²

Default retained activity. Release is permitted without further calculation if retained activity is at or below the screening value — 1,221 MBq (33 mCi) for I-131.
Default dose rate. Release is permitted if the measured dose rate at 1 meter is at or below 0.07 mSv/h (7 mR/h).
Patient-specific calculation. Using measured retained activity or dose rate, the effective half-life, and an occupancy factor, the licensee calculates the projected dose to the maximally exposed individual and may release at higher activities if that dose stays below 5 mSv.

The table below summarizes the decision framework.

Quantity	Default screening value	Regulatory basis
Retained activity allowing release	≤ 1,221 MBq (33 mCi) I-131	10 CFR 35.75; NUREG-1556 Vol 9
Dose rate at 1 m allowing release	≤ 0.07 mSv/h (7 mR/h)	10 CFR 35.75; RG 8.39
TEDE limit to any other individual	5 mSv (0.5 rem)	10 CFR 35.75
Threshold requiring written instructions	Dose to another could exceed 1 mSv	10 CFR 35.75

A worked dose-rate example

Consider a patient whose retained activity has fallen to 33 mCi (1,221 MBq) of I-131. Treating the patient as a point source, the unshielded dose-equivalent rate at 1 meter (100 cm) is:

\dot{X} = \frac{Γ \cdot A}{d ^{2}} = \frac{2.2 \times 33}{10 0 ^{2}} \approx 7.3 \times 1 0^{- 3} R/h \approx 0.073 mSv/h

This is essentially the 0.07 mSv/h screening value — which is exactly why the two default criteria (33 mCi retained and 0.07 mSv/h at 1 m) correspond to one another.²

Now estimate the cumulative dose to a household contact after release. Approximating the exposure as a single exponential in the effective half-life, the time-integrated dose is:

D = 1.44 \cdot \dot{X}_{0} \cdot T_{eff} \cdot E

where the factor 1.44 = 1/ln2 converts a half-life into a mean life. For an initial dose rate of 0.073 mSv/h at 1 m, an effective half-life of $T_{eff} = 0.4$ days (≈ 9.6 h, typical of a rapidly clearing ablation patient), and a conservative combined occupancy-and-distance factor $E = 0.25$ :

D = 1.44 \times 0.073 \times 9.6 \times 0.25 \approx 0.25 mSv

The result is well under the 5 mSv limit, consistent with the low doses actually measured in family members and caregivers when behavioral instructions are followed.⁸⁹¹⁰ The calculation also shows why occupancy and distance restrictions — sleeping apart, limiting close contact — are the levers that make release safe.

What the measured data show

Direct measurements confirm the calculations. Dose-rate measurements from thyroid cancer patients after radioiodine administration, combined with realistic contact times, yield restriction schedules that keep contacts below 1 mSv, and they show that ablation patients clear faster than hyperthyroidism patients.⁸ Dosimetric analysis of released patients supports a 30 mCi (≈1.11 GBq) class of release criteria as consistent with a 5 mSv individual limit.⁶ Thermoluminescent-dosimeter studies of family members of hyperthyroid patients treated with up to 600 MBq found doses well below constraints for all adults and children when European Commission instructions were followed, and direct measurement of caregivers of hospitalized high-activity thyroid cancer patients found total effective dose equivalents of only a few tenths of a millisievert, far below the 5 mSv constraint.⁹¹⁰

Clinical Impact

The radiation safety program determines whether high-activity radioiodine therapy can be delivered safely without turning the nursing unit into an exposure hazard. When room preparation, contamination control, and dosimetry are handled well, caregivers and staff receive small, well-characterized doses and the therapy proceeds normally.

The most consequential decisions are practical:

Admission versus discharge. The release calculation directly affects length of stay, bed use, and cost, so an accurate patient-specific calculation can safely shorten confinement.²
Staff dose management. Nursing dose depends heavily on patient mobility: a self-caring patient exposes staff far less than a totally dependent one. Cumulative nursing dose over the week after treatment can range from a small fraction of a millisievert for a self-caring patient to several millisieverts for a fully dependent patient, so staffing and care planning are radiation-protection decisions.⁸
Contamination events. Vomiting in the hours after administration, or incontinence, can spread significant contamination and is the most common cause of a room decontamination event; anti-emetic planning and absorbent coverings are preventive controls.³

Practical Optimization Tips

Prepare the room before the dose arrives

Room preparation is done in advance, not after admission:¹⁵

Absorbent coverings on the floor around the bed and toilet and on high-touch surfaces (bed rails, call button, remote, door handles, phone).
Dedicated, disposable or held-for-decay linens, gowns, utensils, and trays.
Waste containers lined with plastic bags, clearly labeled, for hold-for-decay storage.
Shielding where practical — portable shields or room design that limits dose to the corridor and adjacent rooms, informed by a survey.
A private sanitary facility, as required, flushed thoroughly after each use.

Control contamination and monitor removals

Because I-131 leaves the body by multiple routes, contamination control is the core task:¹⁵

Staff wear gloves and, when contact is expected, gowns and shoe covers; hands and shoes are surveyed on leaving.
Every item removed from the room is monitored to confirm its radioactivity cannot be distinguished from background on the most sensitive scale, or it is handled as radioactive waste — a direct 10 CFR 35.315 requirement.¹
The room is surveyed for removable and fixed contamination at discharge and decontaminated before release for normal use.

Plan waste handling around decay-in-storage

I-131 waste generated during the stay — bagged linens, gloves, coverings, and dressings — is well suited to decay-in-storage because of the relatively short 8.02-day half-life. After roughly ten half-lives (about eighty days) the activity has fallen by a factor near one thousand, and after the facility's designated hold period the waste can be surveyed and, if indistinguishable from background, released as ordinary waste per the license conditions. Label each bag with the date and nuclide, store it in a shielded, secure, posted area separate from clinical spaces, and log it so the hold period and final survey are documented. Handling I-131 waste this way avoids unnecessary transfers and keeps the material within the facility's controlled program until it is genuinely no longer radioactive.¹³

Manage staff and visitor dose by time, distance, and instruction

Apply the classic controls deliberately:³⁴

Time — cluster nursing tasks to limit time at the bedside.
Distance — perform non-contact tasks from the doorway; the inverse-square law rewards even a step back.
Visitor limits — note on the door or chart where and how long visitors may stay, per 35.315, and restrict pregnant visitors and children.¹
Written instructions — provide the patient with ALARA behavioral instructions at discharge whenever another person's dose could exceed 1 mSv.¹²

Document the release decision

The release calculation, the basis for any patient-specific parameters, the instructions provided, and the discharge survey should all be recorded. NRC guidance and RG 8.39 describe the records to retain, and complete documentation is what makes the release defensible at inspection.¹²

Regulatory Considerations

Inpatient radioiodine therapy sits squarely within the NRC or Agreement State medical-use framework. The relevant authorities are:

10 CFR 35.75 — Release of individuals. Sets the 5 mSv release limit and the 1 mSv instruction threshold.¹
10 CFR 35.310 and 35.315 — Safety instruction and safety precautions. Require training of personnel caring for the patient and the private-room, posting, visitor, monitoring, and notification duties for confined patients.¹
10 CFR Part 20 — Standards for Protection Against Radiation. Sets the occupational limit of 50 mSv/year, the public limit of 1 mSv/year, and the declared-pregnant-worker embryo/fetus limit of 5 mSv over the gestation, along with survey and posting requirements.⁷
NRC Regulatory Guide 8.39, Revision 1. Provides the methods and default values for the patient-release decision and the instructions to patients.²
NUREG-1556 Volume 9, Revision 3. Consolidated guidance for medical-use licenses, including expectations for a therapy program.¹¹
NCRP Report No. 155 and ICRP Publication 94. Consensus guidance on managing radionuclide therapy patients and releasing patients after therapy, including family dose constraints (commonly 5 mSv for adults assisting and 1 mSv for others and children).³⁴

State-specific rules apply on top of the federal framework. In Florida, medical use of radioactive material is administered by the Florida Department of Health, Bureau of Radiation Control under Florida Administrative Code Chapter 64E-5; Florida is an NRC Agreement State, so the state — not the NRC — licenses, inspects, and receives reports. DRPS also serves Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey (Agreement States) and Washington DC and Delaware (direct NRC for radioactive material). Always confirm requirements with the authority having jurisdiction.

Frequently Asked Questions (FAQs)

When must an I-131 therapy patient be hospitalized?

When the patient cannot be released under 10 CFR 35.75 — that is, when the total effective dose equivalent to any other individual could exceed 5 mSv. Higher administered activities for thyroid cancer more often require admission than lower activities for hyperthyroidism.¹²

What does 10 CFR 35.315 require?

A private room with a private sanitary facility (or shared only with another confined therapy patient), a Radioactive Materials posting, documented visitor limits on the door or chart, monitoring of items removed from the room, and prompt notification of the RSO and an authorized user on a medical emergency or death.¹

What is the default release criterion for I-131?

Release is allowed under default screening values when retained activity is at or below 1,221 MBq (33 mCi) or the dose rate at 1 meter is at or below 0.07 mSv/h (7 mR/h); a patient-specific calculation can justify release at higher activities while keeping the dose to others below 5 mSv.²

How much dose do caregivers really receive?

Measured caregiver and family doses are consistently a few tenths of a millisievert — well below the 5 mSv constraint — when distance, contact-time, and sleeping-arrangement instructions are followed.⁹¹⁰

Why is contamination control so central for I-131?

Because iodine is excreted in urine, saliva, sweat, and feces, the room can become contaminated through multiple routes; absorbent coverings, dedicated items, hold-for-decay waste, and monitoring of removals control it.¹⁵

Who is responsible for the program?

The authorized user directs care; the Radiation Safety Officer, supported by a qualified or board-certified medical physicist, sets room preparation, dosimetry, contamination control, and release procedures under the facility's license.³⁴

Key Takeaways

The 5 mSv release limit in 10 CFR 35.75 decides admission; when it cannot be met, 10 CFR 35.315 governs the stay.¹
Default release values for I-131 are 1,221 MBq (33 mCi) retained or 0.07 mSv/h at 1 m — and they correspond to one another.²
I-131 emits a 364 keV gamma and is excreted by multiple routes, so both shielding and contamination control matter.⁵⁶
A patient-specific calculation using effective half-life and occupancy can safely shorten confinement.²
Measured caregiver and family doses are a few tenths of a millisievert when instructions are followed.⁸⁹¹⁰
The program is physicist- and RSO-directed under the NRC or Agreement State license, with documentation that survives inspection.²³

Conclusion

Hospitalizing a radioiodine therapy patient converts a treatment room into a controlled radiation area with specific, enforceable duties. The physics is straightforward — a penetrating 364 keV gamma and multi-route excretion — and the regulatory pivot is the 5 mSv release limit. A program that prepares the room in advance, controls contamination, manages staff and visitor dose by time and distance, performs an accurate release calculation, and documents every step keeps caregivers, visitors, and the public far below dose limits while delivering effective therapy.¹²³⁴

How DRPS Can Help

Diagnostic Radiation Physics Services (DRPS) supports nuclear medicine and radiopharmaceutical-therapy programs across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware with radiation safety officer support, radioactive material license support, therapy-room shielding and contamination-control planning, release-calculation review, and staff training delivered by board-certified medical physicists. Our medical physicist consulting team helps facilities run inpatient I-131 therapy safely and defensibly.

Related Resources

References

U.S. Nuclear Regulatory Commission. 10 CFR Part 35, Medical Use of Byproduct Material (including §§ 35.75, 35.310, and 35.315). ecfr.gov
U.S. Nuclear Regulatory Commission. Release of Patients Administered Radioactive Material. Regulatory Guide 8.39, Revision 1. Washington, DC: NRC; 2020. nrc.gov
National Council on Radiation Protection and Measurements. Management of Radionuclide Therapy Patients. NCRP Report No. 155. Bethesda, MD: NCRP; 2006. ncrponline.org
International Commission on Radiological Protection. Release of patients after therapy with unsealed radionuclides. ICRP Publication 94. Ann ICRP. 2004;34(2). doi:10.1016/j.icrp.2004.08.001. doi.org
National Institute of Standards and Technology. Radionuclide decay data for iodine-131 (half-life 8.02 days; principal gamma 364 keV). nist.gov
Zanzonico PB. Radiation dose to patients and relatives incident to 131I therapy. Thyroid. 1997;7(2):199-204. doi:10.1089/thy.1997.7.199. doi.org
U.S. Nuclear Regulatory Commission. 10 CFR Part 20, Standards for Protection Against Radiation. ecfr.gov
Barrington SF, Kettle AG, O'Doherty MJ, Wells CP, Somer EJ, Coakley AJ. Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid. Eur J Nucl Med. 1996;23(2):123-30. doi:10.1007/BF01731834. doi.org
Cappelen T, Unhjem JF, Amundsen AL, Kravdal G, Følling I. Radiation exposure to family members of patients with thyrotoxicosis treated with iodine-131. Eur J Nucl Med Mol Imaging. 2005;33(1):81-6. doi:10.1007/s00259-005-1888-7. doi.org
Poon N, Chaudakshetrin P, Sritongkul N, Tuntawiroon M. Total effective dose equivalent to caregivers from hospitalized patients treated with high dose radioiodine for thyroid carcinoma. J Med Assoc Thai. 2016;99(2):225-30. pubmed.ncbi.nlm.nih.gov
U.S. Nuclear Regulatory Commission. Consolidated Guidance About Materials Licenses: Program-Specific Guidance About Medical Use Licenses. NUREG-1556, Volume 9, Revision 3. Washington, DC: NRC; 2019. nrc.gov